NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody
drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC
internalization. The additi...
www.cell.com
November 12, 2024 at 12:33 PM
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
gebildet werden, z. B. Cetuximab gegen den EGFR-Rezeptor bei Darm- oder Kopf-Hals-Krebs. Ein anderes Beispiel ist Trastuzumab, das gegen den HER2-Wachstumsfaktor bei manchen Formen von Brustkrebs gerichtet ist und dort aus der Behandlung nicht mehr wegzudenken ist.
January 8, 2025 at 6:27 AM
gebildet werden, z. B. Cetuximab gegen den EGFR-Rezeptor bei Darm- oder Kopf-Hals-Krebs. Ein anderes Beispiel ist Trastuzumab, das gegen den HER2-Wachstumsfaktor bei manchen Formen von Brustkrebs gerichtet ist und dort aus der Behandlung nicht mehr wegzudenken ist.
Excited to see our paper in print in Cancer Discovery @theaacr.bsky.social
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Zongertinib, a covalent HER2 inhibitor, is active in HER2-driven preclinical models and patients and effectively targets HER2 oncogenic signaling while sparing wild-type EGFR, resulting in potent inhi...
aacrjournals.org
January 13, 2025 at 5:33 PM
Excited to see our paper in print in Cancer Discovery @theaacr.bsky.social
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...
Ma quali sono queste alterazioni specifiche? Esempi sono mutazioni di EGFR o fusioni di ALK e ROS nel cancro al polmone o BCR-ABL in alcune leucemie. Mutazioni di BRAF in melanoma, amplificazioni di HER2 nel cancro al seno.
June 15, 2025 at 2:11 PM
Ma quali sono queste alterazioni specifiche? Esempi sono mutazioni di EGFR o fusioni di ALK e ROS nel cancro al polmone o BCR-ABL in alcune leucemie. Mutazioni di BRAF in melanoma, amplificazioni di HER2 nel cancro al seno.
10/1 🧬 Onkologie:
Tumorspezifische Genexpression (z.B. HER2, EGFR) als Ziel für personalisierte Therapie.
Liquid Biopsies kombinieren Genomics & Proteomics aus Blutproben.
Tumorspezifische Genexpression (z.B. HER2, EGFR) als Ziel für personalisierte Therapie.
Liquid Biopsies kombinieren Genomics & Proteomics aus Blutproben.
July 26, 2025 at 10:57 AM
10/1 🧬 Onkologie:
Tumorspezifische Genexpression (z.B. HER2, EGFR) als Ziel für personalisierte Therapie.
Liquid Biopsies kombinieren Genomics & Proteomics aus Blutproben.
Tumorspezifische Genexpression (z.B. HER2, EGFR) als Ziel für personalisierte Therapie.
Liquid Biopsies kombinieren Genomics & Proteomics aus Blutproben.
Researchers at the Harry Perkins Institute discovered that Melittin, the key compound in bee venom, can destroy aggressive breast cancer cell membranes within an hour while sparing healthy cells. In lab tests, it also blocked cancer growth signals like EGFR and HER2 within 20 minutes.
September 8, 2025 at 8:29 AM
Researchers at the Harry Perkins Institute discovered that Melittin, the key compound in bee venom, can destroy aggressive breast cancer cell membranes within an hour while sparing healthy cells. In lab tests, it also blocked cancer growth signals like EGFR and HER2 within 20 minutes.
1/n Have you ever wondered whether an amplified oncogene in a patient’s tumor (HER2/EGFR/CCND1/…) is carried on extrachromosomal DNA (ecDNA) vs embedded within a chromosome? Bulk WGS + genome graph can hint, but in practice it’s often hard to resolve. Here is our new preprint.
February 16, 2026 at 6:49 PM
1/n Have you ever wondered whether an amplified oncogene in a patient’s tumor (HER2/EGFR/CCND1/…) is carried on extrachromosomal DNA (ecDNA) vs embedded within a chromosome? Bulk WGS + genome graph can hint, but in practice it’s often hard to resolve. Here is our new preprint.
Grosso modo, un 40-50% di questi pazienti ha un tumore con un’alterazione gene¬tica che si può definire «azionabile» farmacologicamente. Que¬sti geni possono essere Egfr, Ros1, Alk, Ret, Met, Her2, la mutazione specifica G12C di Kras e altri. Cosa significa?
September 9, 2025 at 10:40 AM
Grosso modo, un 40-50% di questi pazienti ha un tumore con un’alterazione gene¬tica che si può definire «azionabile» farmacologicamente. Que¬sti geni possono essere Egfr, Ros1, Alk, Ret, Met, Her2, la mutazione specifica G12C di Kras e altri. Cosa significa?
The authors of this paper did something similar. One inhibitor allows selection of escape mutants. Hence, the dosed mice with three (working slightly differently) at the same time.
RAS inhibitor daraxonrasib
EGFR/HER2 kinase inhibitor afatini and
5/7
RAS inhibitor daraxonrasib
EGFR/HER2 kinase inhibitor afatini and
5/7
January 31, 2026 at 6:00 PM
The authors of this paper did something similar. One inhibitor allows selection of escape mutants. Hence, the dosed mice with three (working slightly differently) at the same time.
RAS inhibitor daraxonrasib
EGFR/HER2 kinase inhibitor afatini and
5/7
RAS inhibitor daraxonrasib
EGFR/HER2 kinase inhibitor afatini and
5/7
Long-term single-molecule tracking reveals EGFR, HER2, and HER3 dimerization dynamics. Oncogenic mutations stabilize dimerization, impacting signaling. Insights offer new paths for targeted therapies. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5
No description available
www.cell.com
July 19, 2026 at 10:00 AM
Long-term single-molecule tracking reveals EGFR, HER2, and HER3 dimerization dynamics. Oncogenic mutations stabilize dimerization, impacting signaling. Insights offer new paths for targeted therapies. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky 🧪
Study reveals long-term tracking of EGFR, HER2, and HER3 shows oncogenic mutations lead to stable dimerization, disrupting normal activation dynamics. 3 receptors, 1 technique! PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky #Pharmsky #RNA #ASHG 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5
No description available
www.cell.com
August 13, 2026 at 9:00 PM
Did you know that some cancer treatments cause cardiotoxicity?
These include some chemo, radiotherapy, immuno & targeted therapies (including some ALK, EGFR & HER2 inhibitors).
The 🔑 is learning more & integrating cardio oncology into your care team👇
www.oncogeneresearch.org/cardiotoxicity
#lcsm
These include some chemo, radiotherapy, immuno & targeted therapies (including some ALK, EGFR & HER2 inhibitors).
The 🔑 is learning more & integrating cardio oncology into your care team👇
www.oncogeneresearch.org/cardiotoxicity
#lcsm
February 8, 2025 at 3:50 PM
Did you know that some cancer treatments cause cardiotoxicity?
These include some chemo, radiotherapy, immuno & targeted therapies (including some ALK, EGFR & HER2 inhibitors).
The 🔑 is learning more & integrating cardio oncology into your care team👇
www.oncogeneresearch.org/cardiotoxicity
#lcsm
These include some chemo, radiotherapy, immuno & targeted therapies (including some ALK, EGFR & HER2 inhibitors).
The 🔑 is learning more & integrating cardio oncology into your care team👇
www.oncogeneresearch.org/cardiotoxicity
#lcsm
¿Qué es el HER2?
Conoce más sobre este tema en nuestro evento sobre Terapias Dirigidas de Cáncer de Pulmón 2025.
#cáncerdepulmón #HER2 #EGFR
Conoce más sobre este tema en nuestro evento sobre Terapias Dirigidas de Cáncer de Pulmón 2025.
#cáncerdepulmón #HER2 #EGFR
August 9, 2025 at 4:44 PM
¿Qué es el HER2?
Conoce más sobre este tema en nuestro evento sobre Terapias Dirigidas de Cáncer de Pulmón 2025.
#cáncerdepulmón #HER2 #EGFR
Conoce más sobre este tema en nuestro evento sobre Terapias Dirigidas de Cáncer de Pulmón 2025.
#cáncerdepulmón #HER2 #EGFR
Long-term SPT of EGFR, HER2, and HER3 reveals oncogenic EGFR mutations induce stable, ligand-independent dimerization, impacting ErbB signaling dynamics significantly. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5
No description available
www.cell.com
September 12, 2026 at 11:00 PM
ICYMI last year in Cancer Discovery @aacrjournals.bsky.social: Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers – by Birgit Wilding, Ralph Neumüller, et al. doi.org/10.1158/2159...
August 8, 2025 at 7:04 PM
ICYMI last year in Cancer Discovery @aacrjournals.bsky.social: Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers – by Birgit Wilding, Ralph Neumüller, et al. doi.org/10.1158/2159...
¿Qué es el HER2?
Conoce más sobre este tema en nuestro evento sobre Terapias Dirigidas de Cáncer de Pulmón 2025.
#cáncerdepulmón #HER2 #EGFR
Conoce más sobre este tema en nuestro evento sobre Terapias Dirigidas de Cáncer de Pulmón 2025.
#cáncerdepulmón #HER2 #EGFR
August 9, 2025 at 4:43 PM
¿Qué es el HER2?
Conoce más sobre este tema en nuestro evento sobre Terapias Dirigidas de Cáncer de Pulmón 2025.
#cáncerdepulmón #HER2 #EGFR
Conoce más sobre este tema en nuestro evento sobre Terapias Dirigidas de Cáncer de Pulmón 2025.
#cáncerdepulmón #HER2 #EGFR
3 different targets for 4 electrophiles: 2 for BTK, 1 for HER2 and one for EGFR
November 23, 2025 at 4:23 PM
3 different targets for 4 electrophiles: 2 for BTK, 1 for HER2 and one for EGFR
The HER2 TKIs - EGFR TKIs not especially efficacious. First more selective HER2 TKIs - similar with high risk of grade 3 toxicity, aligned with what we saw with 1G and 2G EGFR TKIs. Zongertinib looking interest g from a response and TRAE point #BTOG25
March 3, 2025 at 11:16 AM
The HER2 TKIs - EGFR TKIs not especially efficacious. First more selective HER2 TKIs - similar with high risk of grade 3 toxicity, aligned with what we saw with 1G and 2G EGFR TKIs. Zongertinib looking interest g from a response and TRAE point #BTOG25
The Candida albicans peptide toxin candidalysin can trigger potent innate immune responses in epithelial cells, macrophages and neutrophils. This #mBio review explores the biology of candidalysin and its role in host cell activation: asm.social/2pA
May 15, 2025 at 3:24 PM
The Candida albicans peptide toxin candidalysin can trigger potent innate immune responses in epithelial cells, macrophages and neutrophils. This #mBio review explores the biology of candidalysin and its role in host cell activation: asm.social/2pA
ALK Positive - Moffitt Cancer Center Launches an Enhanced Form of TIL Therapy Study for NSCLC
@alkpositive.bsky.social @moffittnews.bsky.social
oncodaily.com/voices/moffi...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer
@alkpositive.bsky.social @moffittnews.bsky.social
oncodaily.com/voices/moffi...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer
Moffitt Cancer Center Launches an Enhanced Form of TIL Therapy Study for NSCLC - ALK Positive - OncoDaily
Moffitt Cancer Center Launches an Enhanced Form of TIL Therapy Study for NSCLC - ALK Positive / ALK mutations, ALK Positive, cancer, EGFR Mutations, HER2
oncodaily.com
August 16, 2025 at 8:04 PM
ALK Positive - Moffitt Cancer Center Launches an Enhanced Form of TIL Therapy Study for NSCLC
@alkpositive.bsky.social @moffittnews.bsky.social
oncodaily.com/voices/moffi...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer
@alkpositive.bsky.social @moffittnews.bsky.social
oncodaily.com/voices/moffi...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer
Lab-in-the-loop therapeutic antibody design with deep learning
Targets
EGFR
IL6
HER2
OSM
11 lead Ab➡️ 4 rounds with > 3X ⏫binding affinity➡️ > 1800 Ab designs
Hope this system can yield antibodies with better immunohistochemical performance as well
bioRxiv 2025
www.biorxiv.org/content/10.1...
Targets
EGFR
IL6
HER2
OSM
11 lead Ab➡️ 4 rounds with > 3X ⏫binding affinity➡️ > 1800 Ab designs
Hope this system can yield antibodies with better immunohistochemical performance as well
bioRxiv 2025
www.biorxiv.org/content/10.1...
November 18, 2025 at 12:26 PM
Lab-in-the-loop therapeutic antibody design with deep learning
Targets
EGFR
IL6
HER2
OSM
11 lead Ab➡️ 4 rounds with > 3X ⏫binding affinity➡️ > 1800 Ab designs
Hope this system can yield antibodies with better immunohistochemical performance as well
bioRxiv 2025
www.biorxiv.org/content/10.1...
Targets
EGFR
IL6
HER2
OSM
11 lead Ab➡️ 4 rounds with > 3X ⏫binding affinity➡️ > 1800 Ab designs
Hope this system can yield antibodies with better immunohistochemical performance as well
bioRxiv 2025
www.biorxiv.org/content/10.1...
@marie-will.bsky.social expertly setting up a major research focus and our latest work identifying a new resistance mechanism and a rational strategy to improve the efficacy of the HER2 #ADC T-DXd.
Please check it out here: www.cell.com/cell-reports...
Please check it out here: www.cell.com/cell-reports...
November 23, 2024 at 1:58 PM
@marie-will.bsky.social expertly setting up a major research focus and our latest work identifying a new resistance mechanism and a rational strategy to improve the efficacy of the HER2 #ADC T-DXd.
Please check it out here: www.cell.com/cell-reports...
Please check it out here: www.cell.com/cell-reports...
Dr. Christina Baik & Dr. Nathaniel Myall lead experts discussing EGFR mutations, HER2 targeting, and uncommon oncogene drivers with Dr. Lei Deng and Dr. Jonathan Riess at #SFLung25, May 16-17 at San Francisco! Register now: buff.ly/wA6ATOX @fredhutch.bsky.social #MedEd #Medsky #LungCancer #Oncology
May 1, 2025 at 7:01 PM
Dr. Christina Baik & Dr. Nathaniel Myall lead experts discussing EGFR mutations, HER2 targeting, and uncommon oncogene drivers with Dr. Lei Deng and Dr. Jonathan Riess at #SFLung25, May 16-17 at San Francisco! Register now: buff.ly/wA6ATOX @fredhutch.bsky.social #MedEd #Medsky #LungCancer #Oncology
📣 ESMO Oncogene-addicted mNSCLC Living Guideline v1.3 update: New algorithms and recommendations for c-Met overexpression, NRG1 gene fusion, EGFR mutations and HER2 alterations.
🔗 https://ow.ly/82yx50YmhtR
#ClinicalPracticeGuideline
🔗 https://ow.ly/82yx50YmhtR
#ClinicalPracticeGuideline
February 26, 2026 at 2:02 PM
📣 ESMO Oncogene-addicted mNSCLC Living Guideline v1.3 update: New algorithms and recommendations for c-Met overexpression, NRG1 gene fusion, EGFR mutations and HER2 alterations.
🔗 https://ow.ly/82yx50YmhtR
#ClinicalPracticeGuideline
🔗 https://ow.ly/82yx50YmhtR
#ClinicalPracticeGuideline